EU GMP Annex 1 Revision Could Require Firms to Modify or Replace Cleanrooms
This article was originally published in The Gold Sheet
Executive Summary
Cap crimping provision draws fire as U.S. drug makers worry that EU Annex 1 revision could force expensive cleanroom modifications, even as they join EU manufacturers in applauding the revision's relaxation of requirements for particulate control during the manufacture of sterile drug products
You may also be interested in...
PIC/S incorporates Annex 1 of GMP guide
The Pharmaceutical Inspection Convention and Pharmaceutical Inspection Cooperation Scheme, or PIC/S, has adopted the European Union's Annex 1 as part of its PIC/S GMP guide
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”